Key result
Pharmacological therapies provide clinical benefit in advanced heart failure, though poor tolerability requires personalized dosing.
Why the study?
Despite available disease-modifying therapies, about 10% of heart failure patients progress to advanced heart failure, and no large randomized trials have been conducted in this population.
This narrative review summarizes pharmacological strategies for advanced heart failure, emphasizing that while disease-modifying drugs remain beneficial, poor tolerability necessitates a personalized approach such as utilizing low doses of multiple drug classes and careful titration.
Answers are grounded in this paper and cite their sources.
May support personalized dosing in advanced HF; leaves open optimal titration strategies for prospective trials.
Heart failure is one of the leading causes of adverse cardiac outcomes. Despite available disease-modifying therapies, about 10% of patients progress to advanced heart failure. The aim of this review is to summarize pharmacological treatment options for this phase. No large randomized trials have been conducted in patients with advanced heart failure. Most disease-modifying medications are beneficial and their use is recommended, although they are often difficult to tolerate. A personalized approach is needed.
No takes yet. Share an insight, caveat, or question.
Kisheva et al. (2024) conducted a review in Advanced heart failure. Disease-modifying and symptomatic pharmacotherapy (ARNI, ACEi, ARB, beta-blockers, MRA, SGLT2 inhibitors, vericiguat, diuretics, inotropes) was evaluated. Pharmacological therapies provide clinical benefit in advanced heart failure, though poor tolerability requires personalized dosing.
Synapse has enriched 10 related papers. Consider them for comparative context: